GSK's targeted cancer therapy shows positive results in late-stage study
10/07/2026 12:37
GSK's targeted cancer therapy shows positive results in late-stage study July 10 (Reuters) - British drugmaker GSK's GSK.L experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
GSK has licensed the drug from China's Hansoh Pharma 3692.HK.
(Reporting by Prerna Bedi in Bengaluru; Editing by Shilpi Majumdar)
((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion